Literature DB >> 27057213

Evaluation of hyperglycaemic response to intra-operative dexamethasone administration in patients undergoing elective intracranial surgery: A randomised, prospective study.

Rakesh Sethi1, Imtiaz A Naqash2, Sukhminder Jit Singh Bajwa1, Vikas Dutta1, Altaf Umar Ramzan2, Syed Amir Zahoor3.   

Abstract

BACKGROUND AND AIM: The glucocorticoid dexamethasone in a bolus dose of 8-10 mg followed by quarterly dose of 4 mg is commonly used during intracranial surgery so as to reduce oedema and vascular permeability. However, the detrimental hyperglycaemic effects of dexamethasone may override its potentially beneficial effects. The present prospective, randomised study aimed at comparing the degree and magnitude of hyperglycaemia induced by prophylactic administration of dexamethasone in patients undergoing elective craniotomy.
MATERIALS AND METHODS: Sixty American Society of Anaesthesiologist (ASA) grade-I and II patients were randomly assigned to three groups of 20 patients each. Group-I received dexamethasone during surgery for the first time. Group-II received dexamethasone in addition to receiving it pre-operatively, whereas Group-III (control group) patients were administered normal saline as placebo. Baseline blood glucose (BG) was measured in all the three groups before induction of anaesthesia and thereafter after every hour for 4 h and then two-hourly. Besides intra- and intergroup comparison of BG, peak BG concentration was also recorded for each patient. Statistical analysis was carried out with analysis of variance (ANOVA) and Student's t-test and value of P < 0.05 was considered statistically significant.
RESULTS: Baseline BG reading were higher and statistically significant in Group-II as compared with Group-I and Group-III (P < 0.05). However, peak BG levels were significantly higher in Group-I than in Group-II and III (P < 0.05). Similarly, the magnitude of change in peak BG was significantly higher in Group-I as compared to Group-II and III (P < 0.05).
CONCLUSION: Peri-operative administration of dexamethasone during neurosurgical procedures can cause significant increase in BG concentration especially in patients who receive dexamethasone intra-operatively only.

Entities:  

Keywords:  Dexamethasone; hyperglycaemic response; intracranial surgery

Year:  2016        PMID: 27057213      PMCID: PMC4802961          DOI: 10.4103/1793-5482.177660

Source DB:  PubMed          Journal:  Asian J Neurosurg


  13 in total

Review 1.  Glucose modulation of ischemic brain injury: review and clinical recommendations.

Authors:  C T Wass; W L Lanier
Journal:  Mayo Clin Proc       Date:  1996-08       Impact factor: 7.616

Review 2.  Dexamethasone for intracranial neurosurgery and anaesthesia.

Authors:  Brad Hockey; Kate Leslie; Daryl Williams
Journal:  J Clin Neurosci       Date:  2009-08-07       Impact factor: 1.961

3.  Neurologic outcome and blood glucose levels during out-of-hospital cardiopulmonary resuscitation.

Authors:  W T Longstreth; P Diehr; L A Cobb; R W Hanson; A D Blair
Journal:  Neurology       Date:  1986-09       Impact factor: 9.910

4.  Hyperglycemia in patients administered dexamethasone for craniotomy.

Authors:  Michael B Lukins; Pirjo H Manninen
Journal:  Anesth Analg       Date:  2005-04       Impact factor: 5.108

5.  Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery.

Authors:  P Hans; A Vanthuyne; P Y Dewandre; J F Brichant; V Bonhomme
Journal:  Br J Anaesth       Date:  2006-05-12       Impact factor: 9.166

6.  Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization.

Authors:  K L Leenders; R P Beaney; D J Brooks; A A Lammertsma; J D Heather; C G McKenzie
Journal:  Neurology       Date:  1985-11       Impact factor: 9.910

7.  Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome.

Authors:  Tracey A Baird; Mark W Parsons; Thanh Phan; Thanh Phanh; Ken S Butcher; Patricia M Desmond; Brian M Tress; Peter G Colman; Brian R Chambers; Stephen M Davis
Journal:  Stroke       Date:  2003-07-31       Impact factor: 7.914

8.  Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank Attenello; Khoi Than; Amado Jimenez Ruiz; Alessandro Olivi; Alfredo Quiñones-Hinojosa
Journal:  Neurosurgery       Date:  2008-08       Impact factor: 4.654

9.  Genesis of the use of corticosteroids in the treatment and prevention of brain edema.

Authors:  Shearwood McClelland; Donlin M Long
Journal:  Neurosurgery       Date:  2008-04       Impact factor: 4.654

10.  Effect of single-dose dexamethasone on blood glucose concentration in patients undergoing craniotomy.

Authors:  Jeffrey J Pasternak; Diana G McGregor; William L Lanier
Journal:  J Neurosurg Anesthesiol       Date:  2004-04       Impact factor: 3.956

View more
  4 in total

1.  Adverse side effects of dexamethasone in surgical patients.

Authors:  Jorinde Aw Polderman; Violet Farhang-Razi; Susan Van Dieren; Peter Kranke; J Hans DeVries; Markus W Hollmann; Benedikt Preckel; Jeroen Hermanides
Journal:  Cochrane Database Syst Rev       Date:  2018-08-28

2.  Effect of high-dose dexamethasone on patients without diabetes during elective neurosurgery: a prospective study.

Authors:  Majid Alabbood; Min Ling; Kenneth Ho
Journal:  Diabetol Int       Date:  2018-08-27

3.  Comparison of Two Protocols in the Management of Glucocorticoid-induced Hyperglycemia among Hospitalized Patients.

Authors:  Om J Lakhani; Surender Kumar; Sudhir Tripathi; Mitali Desai; Chandani Seth
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec

4.  Adverse side effects of dexamethasone in surgical patients.

Authors:  Jorinde Aw Polderman; Violet Farhang-Razi; Susan Van Dieren; Peter Kranke; J Hans DeVries; Markus W Hollmann; Benedikt Preckel; Jeroen Hermanides
Journal:  Cochrane Database Syst Rev       Date:  2018-11-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.